Summa rerum genera esse tantum duo: substantiam nimirum & accidens, ex suffragio ampliss. facult. philos. in florentissimo ad Auram Athenaeo, sub umbone ... dn. mag. Simonis Tålpo, met & log. professoris famigeratissimi, consistorii Acad. assessoris gravissimi nec non annexae Pijkensis pastoris longe fidelissimi. Summos in philosophia honores aditurus dissertatione philosophica ad sobrie philosophantium examen modeste delata statuere conabitur Jeremias Wallenius J. f. Tavastensis. Ad diem 21. Nov. anni redempti orbis M. DC. XC. IV. Horis pomeridianis in auditorio maximo

Invokaatio: A.J.

Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants

Aluminum salts have been widely used in vaccine formulations and, after their introduction more than 80 years ago, only few vaccine formulations using new adjuvants were developed in the last two decades. Recent advances in the understanding of how innate mechanisms influence the adaptive immunity opened up the possibility for the development of new adjuvants in a more rational design. The purpose of this review is to discuss the recent advances in this field regarding the attempts to determine the molecular basis and the general mechanisms underlying the development of new adjuvants, with particular emphasis on the activation of receptors of innate immune recognition. One can anticipate that the use of these novel adjuvants will also provide a window of opportunities for the development of new vaccines.

Positiones philosophicae ex fragrantissimo philosophiae viridario carptìm collectae. Quas ex consensu amplissimae [et] venerandae facultatis philosophicae in Regiâ Academiâ Aboënsi. Sub praesidio, ... dn. Michaelis Gyllenstålpes, Wexionii, j. u. & philos: doct: pereximii, ll:m polit: & hist: prof: publ: celeberrimi, p. t. rectoris magnifici, moecenatis, praecept. ac promotoris quovis obsequii & honoris genere plurimùm prosequendi. Liberalis exercitij gratia, publicae eruditorum disquisitioni modestè sistit Daniel B. Rosander Smolandus s. r. m.tis stipendiarius. In auditorio majori ad diem 22. Novemb. anno 1654. Horis ab 8. antemeridianis

Variantti A.

De Sveo-Gothis; qui vixerunt sub periodo Erici I.mi. ad Ericum 2.dum: memorans quomodo restituti sunt primum ab Erico, mox tamen ac multos annos ab incertis ducibus vexati, at nunquam vera religione destituti

Variantti B.

De Sveo-Gothis; qui vixerunt sub periodo Erici I.mi. ad Ericum 2.dum: memorans quomodo restituti sunt primum ab Erico, mox tamen ac multos annos ab incertis ducibus vexati, at nunquam vera religione destituti

Variantti A.

De Sveo-Gothis, qui vixerunt sub finem Testamenti Veteris, post praemissa nonnulla de Biarmorum Jumala, expendens quomodo hic verus Deus et Sathanam tunc strinxit circa religionis curam apud paganos, et sibi quosdam alios servavit pios adminiculis variis auctos

Variantti B.

Vancomycin-resistant enterococcus outbreak in a pediatric intensive care unit: report of successful interventions for control and prevention

The objective of this study is to retrospectively report the results of interventions for controlling a vancomycin-resistant enterococcus (VRE) outbreak in a tertiary-care pediatric intensive care unit (PICU) of a University Hospital. After identification of the outbreak, interventions were made at the following levels: patient care, microbiological surveillance, and medical and nursing staff training. Data were collected from computer-based databases and from the electronic prescription system. Vancomycin use progressively increased after March 2008, peaking in August 2009. Five cases of VRE infection were identified, with 3 deaths. After the interventions, we noted a significant reduction in vancomycin prescription and use (75% reduction), and the last case of VRE infection was identified 4 months later. The survivors remained colonized until hospital discharge. After interventions there was a transient increase in PICU length-of-stay and mortality. Since then, the use of vancomycin has remained relatively constant and strict, no other cases of VRE infection or colonization have been identified and length-of-stay and mortality returned to baseline. In conclusion, we showed that a bundle intervention aiming at a strict control of vancomycin use and full compliance with the Hospital Infection Control Practices Advisory Committee guidelines, along with contact precautions and hand-hygiene promotion, can be effective in reducing vancomycin use and the emergence and spread of vancomycin-resistant bacteria in a tertiary-care PICU.

Linea omnes dati generis determinato sub angulo secans in spatio trium dimensionum investigans

Dedikaatio: Fredrika Wilhelmina Stjernvall född Charpentier [ruots.].

Recombinant vaccines and the development of new vaccine strategies

Vaccines were initially developed on an empirical basis, relying mostly on attenuation or inactivation of pathogens. Advances in immunology, molecular biology, biochemistry, genomics, and proteomics have added new perspectives to the vaccinology field. The use of recombinant proteins allows the targeting of immune responses focused against few protective antigens. There are a variety of expression systems with different advantages, allowing the production of large quantities of proteins depending on the required characteristics. Live recombinant bacteria or viral vectors effectively stimulate the immune system as in natural infections and have intrinsic adjuvant properties. DNA vaccines, which consist of non-replicating plasmids, can induce strong long-term cellular immune responses. Prime-boost strategies combine different antigen delivery systems to broaden the immune response. In general, all of these strategies have shown advantages and disadvantages, and their use will depend on the knowledge of the mechanisms of infection of the target pathogen and of the immune response required for protection. In this review, we discuss some of the major breakthroughs that have been achieved using recombinant vaccine technologies, as well as new approaches and strategies for vaccine development, including potential shortcomings and risks.

Challenges in the research and development of new human vaccines

The field of vaccinology was born from the observations by the fathers of vaccination, Edward Jenner and Louis Pasteur, that a permanent, positive change in the way our bodies respond to life-threatening infectious diseases can be obtained by specific challenge with the inactivated infectious agent performed in a controlled manner, avoiding the development of clinical disease upon exposure to the virulent pathogen. Many of the vaccines still in use today were developed on an empirical basis, essentially following the paradigm established by Pasteur, “isolate, inactivate, and inject” the disease-causing microorganism, and are capable of eliciting uniform, long-term immune memory responses that constitute the key to their proven efficacy. However, vaccines for pathogens considered as priority targets of public health concern are still lacking. The literature tends to focus more often on vaccine research problems associated with specific pathogens, but it is increasingly clear that there are common bottlenecks in vaccine research, which need to be solved in order to advance the development of the field as a whole. As part of a group of articles, the objective of the present report is to pinpoint these bottlenecks, exploring the literature for common problems and solutions in vaccine research applied to different situations. Our goal is to stimulate brainstorming among specialists of different fields related to vaccine research and development. Here, we briefly summarize the topics we intend to deal with in this discussion.

Observationes nonnullae super naturam phrenoshematum [!]. Qvas consentiente ampliss: facultate philosophica in Regia Academia Aboënsi, sub praesidio, ... dn. Torst. Rudeen, poës. profess. ord. h. t. facult. phil. decani spectabilis, publici speciminis loco bonis examinandas modestè exhibet Jonas Emzeen, Wermel: ad d. 30 Aprilis anni 1697 loco [et] horis adsuetis

Variantti B.

Nova ratione determinantur loca telluris, ab effectibus parallaxis in transitu planetarum sub sole, dependentia

Arkit: A-B4.

De lingvis sub imperio Sveo-Gothico usitatioribus

Invokaatio: Favente Jehovâ.

Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission

Treatments for patients with hematologic malignancies not in remission are limited, but a few clinical studies have investigated the effects of salvaged unrelated cord blood transplantation (CBT). We retrospectively studied 19 patients with acute leukemia, 5 with myelodysplastic syndrome (MDS with refractory anemia with excess blasts [RAEB]), and 2 with non-Hodgkin's lymphoma who received 1 CBT unit ≤2 loci human leukocyte antigen (HLA)-mismatched after undergoing myeloablative conditioning regimens between July 2005 and July 2014. All of them were in non-remission before transplantation. The infused total nucleated cell (TNC) dose was 4.07 (range 2.76-6.02)×107/kg and that of CD34+ stem cells was 2.08 (range 0.99-8.65)×105/kg. All patients were engrafted with neutrophils that exceeded 0.5×109/L on median day +17 (range 14-37 days) and had platelet counts of >20×109/L on median day +35 (range 17-70 days). Sixteen patients (61.5%) experienced pre-engraftment syndrome (PES), and six (23.1%) patients progressed to acute graft-versus-host disease (GVHD). The cumulative incidence rates of II-IV acute GVHD and chronic GVHD were 50% and 26.9%, respectively. After a median follow-up of 27 months (range 5-74), 14 patients survived and 3 relapsed. The estimated 2-year overall survival (OS), disease-free survival (DFS), and non-relapse mortality (NRM) rates were 50.5%, 40.3%, and 35.2%, respectively. Salvaged CBT might be a promising modality for treating hematologic malignancies, even in patients with a high leukemia burden.

HPV vaccines: a controversial issue?

Controversy still exists over whether the benefits of the available HPV vaccines outweigh the risks and this has suppressed uptake of the HPV vaccines in comparison to other vaccines. Concerns about HPV vaccine safety have led some physicians, healthcare officials and parents to withhold the recommended vaccination from the target population. The most common reason for not administering the prophylactic HPV vaccines are concerns over adverse effects. The aim of this review is the assessment of peer-reviewed scientific data related to measurable outcomes from the use of HPV vaccines throughout the world with focused attention on the potential adverse effects. We found that the majority of studies continue to suggest a positive risk-benefit from vaccination against HPV, with minimal documented adverse effects, which is consistent with other vaccines. However, much of the published scientific data regarding the safety of HPV vaccines appears to originate from within the financially competitive HPV vaccine market. We advocate a more independent monitoring system for vaccine immunogenicity and adverse effects to address potential conflicts of interest with regular systematic literature reviews by qualified individuals to vigilantly assess and communicate adverse effects associated with HPV vaccination. Finally, our evaluation suggests that an expanded use of HPV vaccine into more diverse populations, particularly those living in low-resource settings, would provide numerous health and social benefits.